The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized trial of oral cyclophosphamide (C) with or without veliparib (V), an oral poly (ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent BRCA-positive ovarian, or primary peritoneal or high-grade serous ovarian carcinoma.
Shivaani Kummar
No relevant relationships to disclose
Amit M. Oza
No relevant relationships to disclose
Gini F. Fleming
No relevant relationships to disclose
Daniel Sullivan
No relevant relationships to disclose
David R. Gandara
No relevant relationships to disclose
Charles Erlichman
No relevant relationships to disclose
Miguel Angel Villalona-Calero
No relevant relationships to disclose
Robert Morgan
No relevant relationships to disclose
Alice P. Chen
No relevant relationships to disclose
Jiuping Jay Ji
No relevant relationships to disclose
Deborah Allen
No relevant relationships to disclose
Chih-Jian Lih
No relevant relationships to disclose
Seth M. Steinberg
No relevant relationships to disclose
P. Mickey Williams
No relevant relationships to disclose
Barbara A. Conley
No relevant relationships to disclose
James H. Doroshow
No relevant relationships to disclose